2021 Fiscal Year Final Research Report
Development of a differentiation method for parathyroid cells from human iPS cells
| Project/Area Number |
19K10179
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 57040:Regenerative dentistry and dental engineering-related
|
|---|
| Research Institution | Osaka Dental University (2021)
Kansai Medical University (2019-2020) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | 副甲状腺 / iPS細胞 |
|---|
| Outline of Final Research Achievements |
In this study, we established a new method of inducing the differentiation of parathyroid cells from human iPS cells based on embryologic development. We also succeeded in identifying differentiated parathyroid cells using an immunofluorescence analysis and flow cytometric analyses. Furthermore, we determined whether TGFα/epidermal growth factor receptor (EGFR) signaling, which is considered to be one of the causative pathways of parathyroid hyperplasia, is involved in the parathyroid cell proliferation that was observed in our differentiation model. As a result, the number of differentiated parathyroid cells increased due to TGFα stimulation. On the other hand, the number of differentiated parathyroid cells decreased due to the administration of erlotinib, which is an EGFR antagonist. Thus, using our method, we enabled the evaluation of the mechanism underlying parathyroid hyperplasia, as it mimics the developmental process of the parathyroid gland.
|
| Free Research Field |
幹細胞生物学
|
| Academic Significance and Societal Importance of the Research Achievements |
副甲状腺は骨の代謝に重要な臓器であるが、in vitroでの副甲状腺細胞の維持培養が実現していない。そのため、副甲状腺過形成などの副甲状腺疾患における治療法や医薬品の開発が進展してこなかった。副甲状腺過形成のメカニズム解明や副甲状腺疾患治療薬の開発において、本研究の成果である副甲状腺細胞分化誘導法は非常に有用であり、過形成の抑制薬スクリーニングに応用することで、副甲状腺機能亢進症の根治的な治療薬の開発に寄与することができると考えられる。
|
